

University of Groningen

## Hemostatic changes and antithrombotic management in kidney transplantation

van den Berg, Tamar

DOI:  
[10.33612/diss.254092051](https://doi.org/10.33612/diss.254092051)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2022

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*  
van den Berg, T. (2022). *Hemostatic changes and antithrombotic management in kidney transplantation*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.  
<https://doi.org/10.33612/diss.254092051>

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

# Perioperative antithrombotic therapy does not increase the incidence of early postoperative thromboembolic complications and bleeding in kidney transplantation.

*Transplant International* 2019 Apr;32(4):418-430.

Tamar A.J. van den Berg  
Robert. C. Minnee  
Ton Lisman  
Gertrude J. Nieuwenhuijs-Moeke  
Jacqueline van de Wetering  
Stephan J. L. Bakker  
Robert A. Pol

# 2

## **ABSTRACT**

Perioperative antithrombotic therapy could play a role in preventing thromboembolic complications (TEC) after kidney transplantation (KTx), but little is known on postoperative bleeding risks. This retrospective analysis comprises 2000 single-organ KTx recipients transplanted between 2011 and 2016 in the two largest transplant centers of the Netherlands. TEC and bleeding events were scored  $\leq 7$  days post-KTx. Primary analyses were for associations of antithrombotic therapy with incidence of TEC and bleeding. Secondary analyses were for associations of other potential risk factors. Mean age was  $55 \pm 14$  years, 59% was male and 60% received a living donor kidney. Twenty-one patients (1.1%) had a TEC. Multiple donor arteries [OR 2.79 (1.15-6.79)] and obesity [OR 2.85 (1.19-6.82)] were identified as potential risk factors for TEC. Bleeding occurred in 88 patients (4.4%) and incidence varied significantly between different antithrombotic therapies ( $P=0.006$ ). Cardiovascular disease [OR 2.01 (1.18-3.42)], pre-emptive KTx [OR 2.23 (1.28-3.89)], postoperative heparin infusion (OR 1.69 [1.00-2.85]), and vitamin K antagonists [OR 6.60 (2.95-14.77)] were associated with an increased bleeding risk. Intraoperative heparin and antiplatelet therapy were not associated with increased bleeding risk. These regimens appear to be safe for the possible prevention of TEC without increasing the risk for bleeding after KTx.

## INTRODUCTION

Renal graft thrombosis (RGT) is a serious complication after kidney transplantation (KTx) and a major risk factor for impaired graft function and graft loss.<sup>1</sup> Although RGT is rare, varying from 0.5% to 8%,<sup>1-5</sup> it has high morbidity and mortality and accounts for up to 45% of graft loss in the first post-transplantation phase.<sup>2,6</sup> Known risk factors for RGT are donor age <6 or >60 years, recipient age <5 or >50 years, cold ischemic time (CIT) >24 hours, atherosclerosis in the external iliac, common iliac or renal artery, right donor kidneys, prior peritoneal dialysis, diabetes mellitus, previous thrombosis in the recipient, technical difficulties and hemodynamic instability during transplantation.<sup>7</sup> RGT, deep venous thrombosis (DVT) and pulmonary embolisms (PE) are collectively known as thromboembolic complications (TEC). Incidence of TEC after KTx is reported to vary between 0.6% and 9.1%.<sup>8-11</sup> The wide ranges reported are due to differences in study populations, with highest incidences found in pediatric KTx and lowest in studies involving living donor KTx.<sup>1-4,12</sup> In the KTx population, risk factors for DVT are age >40 years, diabetes mellitus, previous DVT and simultaneous pancreas-kidney transplantation.<sup>1,8,10,11</sup> Since more elderly patients with higher comorbidity are being transplanted, incidence of TEC is likely to increase.<sup>8,13</sup> In vascular surgery, intraoperative administration of heparin is common with the aim to avoid thrombus formation at the anastomoses and clamp sites.<sup>14,15</sup> In KTx, no consensus or protocol for anticoagulants exists. A common argument is the general belief that dialysis-dependent patients, in contrast to pre-emptive patients, are at greater risk for bleeding because of combined effects of uremia, residual effect of heparin used during dialysis and continuous platelet activation, and thus exhaustion, through contact with the dialysis membrane.<sup>16</sup> However, recent insights show that dialysis-dependent and pre-emptive patients have comparable hemostatic profiles preoperatively and are at risk of both bleeding and thrombotic complications.<sup>16-18</sup> Risk of thrombosis should always be carefully weighed against risk of bleeding, but evidence suggests that the benefits of antithrombotic prophylaxis to prevent postoperative thrombosis outweigh the risks of bleeding in procedures such as KTx.<sup>19</sup> The aim of this study was to assess early TEC and bleeding after KTx in relation to perioperative antithrombotic prophylaxis.

## MATERIALS AND METHODS

### Study population

This retrospective cohort analysis comprises all adult KTx recipients in two large tertiary university-based hospitals in the Netherlands, the University Medical Center Groningen (UMCG) and the Erasmus Medical Center in Rotterdam (EMC), transplanted between 2011 and 2016. Exclusion criteria for this study were combined transplantations (36 patients), lack of data on antithrombotic therapy (eight patients), or inaccessible hospital records (13 patients). A total cohort of 2,000 patients was further analyzed.

Patient charts were screened using the electronic hospital registries for baseline characteristics, surgical details, postoperative complications, patient and graft outcome and preoperative antithrombotic prophylaxis (Table 1 and 2). Included were the following agents with their Anatomical Therapeutic Chemical (ATC) classification code: vitamin K antagonists (VKA; phenprocoumon B01AA04 and acenocoumarol B01AA07), low-molecular-weight heparin (LMWH; dalteparin B01AB04 and nadroparin B01AB06), platelet function inhibitors (clopidogrel B01AC04, aspirin B01AC06, dipyridamole B01AC07, carbasalate calcium B01AC08, prasugrel B01AC22 and ticagrelor B01AC24), novel oral anticoagulants (NOACs; dabigatran B01AE07, rivaroxaban B01AF01, apixaban B01AF02 and edoxaban B01AF03) and intraoperative unfractionated heparin (UFH) B01AB01.

For this study, the Medical Ethical Committee (MEC) of the UMCG granted dispensation from the Medical Research Involving Human Subjects Act (WMO) obligation (registration no. MEC2016.601) and this dispensation was submitted to and approved by the MEC of the EMC. Patient data were processed and stored according to the declaration of Helsinki – Ethical principles for medical research involving human subjects. The clinical and research activities are consistent with the Principles of the Declaration of Istanbul as outlined in the “Declaration of Istanbul on Organ Trafficking and Transplant Tourism.”

### **Outcome measures**

Primary outcome measures were associations of antithrombotic therapy with incidence of TEC and bleeding. Secondary analyses were for associations of other potential risk factors.

### **Surgical procedure and center-based immunosuppressive and antithrombotic protocol**

Kidney transplantation was performed with either a living or deceased donor kidney (donation after brain death (DBD) or circulatory death (DCD)). According to the protocol within EuroTransplant, DBD donors received 20 000 IU of heparin prior to systemic perfusion and flushout. DCD and living donors do not receive any form of anticoagulation. After procurement, kidneys were flushed and perfused with cold University of Wisconsin solution (ViaSpan; DuPont, Wilmington, NC, USA; Belzer UW; Bridge to life, Columbia, SC, USA) and placed in either cold storage or using hypothermic machine perfusion (national protocol for all deceased donor kidneys since January 2016). No heparin was added to the perfusates (cold storage or machine perfusion). No subcutaneous heparin was given to recipients intraoperatively. KTx was performed according to local protocol and published before.<sup>20,21</sup> Multiple artery reconstruction was performed in either an end-to-end or end-to-side fashion in both centers. In some deceased donors, attachment to the aortic patch was possible and thus reconstruction was not needed and sometimes the second artery was too small, so it was sacrificed. At the UMCG, patients transplanted pre-emptively received 5000 IU UFH intravenously before clamping of the iliac vessels. In the UMCG, Mannitol is given prior to reperfusion. In both centers, no

additional diuretics are administered. Intraoperative diuresis was defined as visible urine coming from the ureter before ureter-bladder anastomosis or through the urinary catheter in case of absent diuresis prior to surgery. All patients received induction therapy with basiliximab, or occasionally anti-thymocyte globulin, with exception of recipients with human leukocyte antigen (HLA) mismatch of 000. Maintenance immuno-suppression consisted of prednisolone, mycophenolic acid, and tacrolimus. Between 2011 and 2013, patients at the EMC were treated with 12 000 IU/24 h of continuous UFH (without sequential APTT measurements) for 5 days after transplantation, starting 6 h postoperatively. In 2013, this protocol was changed and thereafter only recipients of a kidney with reconstruction of multiple arteries were treated with 12 000 IU/24 h of continuous UFH for 5 days. All patients who did not receive postoperative heparin infusion were given a prophylactic dose of 2850 IU LMWH s.c. as part of hospital protocol for immobilized patients, starting 6h postoperatively. Three patients with history of heparin-induced thrombocytopenia were excluded from this protocol and some patients received therapeutic doses of LMWH, which was adjusted according to renal function.

### **Antithrombotic strategies**

Antithrombotic therapy was divided into five groups: none (control group, CG; n=1333), intraoperative UFH (UFH; n=195), continued use of VKA (n=53), continued use of antiplatelet therapy (APT; n=390), and combined continued use of APT and UFH (APT + UFH; n=29). Patients receiving dual APT (n=9) were combined with patients receiving single APT and analyzed as one group. None of the patients used a NOAC at time of surgery. Continued use of VKA was defined as an preoperative INR >1.5, which was not corrected and last administration was given at day of transplantation. Patients of whom VKA therapy was bridged with heparin were included in the VKA group (n=25). VKA in the 18 patients with a living donor were ceased 3-5 days prior to transplantation and bridged with heparin. The seven patients with a deceased donor were first corrected for INR by Vitamin K/phytomenadione or prothrombin complex concentrate after admission to the hospital and then bridged with heparin. Twenty-nine patients of CG-group had a pre-transplant anticoagulation regime, but were adequately and timely corrected for INR prior to surgery. In the APT group, two patients received platelet transfusion prior to surgery because clopidogrel was not discontinued.

### **Thromboembolic and bleeding complications**

After KTx, diagnoses of TEC were made based on clinical symptoms or laboratory abnormalities and confirmed with duplex imaging, renal scintigraphy or CT-scan. DVT, extending to the popliteal vein or more proximally, all cases of PE and thrombosis of the femoral artery, confirmed by radiological imaging  $\leq 7$  days after surgery, were counted as events. Furthermore, all radiologically or surgically confirmed cases of renal artery or renal vein thrombosis  $\leq 7$  days post-transplantation were counted as an event. Cases of postoperative bleeding  $\leq 7$  days were extracted from follow-up documentation. Clinical symptoms suspected for bleeding, i.e., pain

due to compression or conjunctival pallor, had to be accompanied by either a sudden drop of hemoglobin, noticed by the treating physician, or compression on the graft as confirmed on imaging. Bleeding requiring further intervention, by blood transfusion, re-exploration or both, was then counted as event.

### **Statistical methods and analyses**

Descriptive statistics were presented as mean  $\pm$  standard deviation (SD) or median with interquartile range (IQR) for continuous variables and analyzed by student's *t*-test, ANOVA, Mann-Whitney *U* or Kruskal-Wallis test depending on distribution, evaluated by Shapiro Wilk-test. Categorical variables were presented as total with percentages (n (%)). Differences between patients with and without complications after transplantation were evaluated by Chi-square and/or Fisher's exact tests. Primary analyses focused on univariable regression analysis to determine relationship between perioperative antithrombotic therapy and incidence of TEC and bleeding. Secondary analyses focused on multivariable regression analysis to adjust for potential confounders. Results of the regression analyses were presented as odds ratio (OR) with 95% confidence interval (CI) and its corresponding *P*-value. Tests of significance are two-tailed with significance set at  $P < 0.05$ . A  $P < 0.2$  in univariable analysis and/or known risk factors from the literature were added to the adjusted multivariable model. Hosmer-Lemeshow test was used to test fitness of the model. The model was considered fit when  $P > 0.05$ . Internal validation was performed using bootstrap sampling with 1000 resamples. Discrimination of the model was evaluated using Harrell's C-index. Incidence of TEC was analyzed as percent of patients experiencing TEC  $\leq 7$  days after transplantation. Time to TEC and time to bleeding was calculated from day of transplantation until day of diagnosis as described above. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS v22; IBM Corp, Armonk, NY, USA) and graphs were created using GraphPad Prism v5.04 (GraphPad Software Inc.©, La Jolla, CA, USA).


## **RESULTS**

Baseline characteristics and pre- and intraoperative parameters stratified for TEC and bleeding are shown in Table 1 (TEC) and Table 2 (Bleeding). Mean age of the total cohort was  $54 \pm 14$  years and 60% of patients were male.


### **Incidences of TEC**

Twenty-one patients ( $n=21/2000$ , 1.1%) developed TEC  $\leq 7$  days after KTx. Fourteen (14/21, 67%) TEC developed in patients who did not receive any form of antithrombotic therapy and three (14%) in patients treated with APT. The groups VKA and APT+UFH each had 1 patient with an event of TEC ( $n=1$ , 5%) (Fig. 1). Two patients (11%) receiving UFH had an event of TEC. Of all TEC, 19 were RGT, one case of arterial thrombosis was found in the common femoral artery (day 1)

and in one case DVT occurred (day 7). Incidence of TEC did not vary between the treatment groups ( $P=0.69$ ). Median time for the development of TEC was 1 day (1–3) ( $n=13$ , 62%) (Fig. 2).



**Figure 1.** Incidence (%) of thromboembolic complications per treatment group. TEC, thromboembolic complications; APT, antiplatelet therapy; VKA, Vitamin K antagonists; UFH, unfractionated heparin (given intraoperatively).



**Figure 2.** Number of TEC and bleeding per day after transplantation. n, number of group; TEC, thromboembolic complication



**Table 1.** Incidence of postoperative TEC and baseline characteristics.

| Baseline characteristics of KTx patients |                             | Cases       |             |         |
|--|-----------------------------|-------------|-------------|---------|
| Characteristics                          |                             | No TEC      | TEC ≤7 days | P-value |
| <b>N</b>                                 |                             | 1979        | 21          |         |
| <b>Gender</b>                            | Male (%)                    | 1198        | 10          | 0.23    |
| <b>Age in years</b>                      | 50                          | 1304        | 12          | 0.40    |
| <b>Preemptive KTx</b>                    | Hemodialysis                | 611         | 7           | 0.81    |
| <b>Dialysis-dependent KTx</b>            | CAPD                        | 1035        | 9           |         |
|  |                             | 330         | 5           | 0.32    |
| <b>Months of dialysis</b>                |                             | 22 ± 27     | 18 ± 19     | 0.51    |
| <b>Ethnicity</b>                         | Non-Caucasian               | 264         | 1           | 0.50    |
| <b>ASA score</b>                         |                             | 3 (3 – 3)   | 3 (3 – 3)   | 0.51    |
| <b>BMI in kg/m<sup>2</sup></b>           | ≥30                         | 412         | 9           | 0.01    |
| <b>Baseline eGFR</b>                     | ≥10                         | 604         | 6           | 0.83    |
| <b>CCI score</b>                         |                             | 4 (3 – 6)   | 4 (3 – 6)   | 0.94    |
| <b>Co-morbidities</b>                    | Diabetes                    | 400         | 5           | 0.60    |
|  | SLE                         | 26          | 1           | 0.25    |
|  | Cardiovascular disease      | 465         | 4           | 0.80    |
|  | Peripheral vascular disease | 162         | 1           | 0.99    |
|  | Hypertension                | 1171        | 11          | 0.70    |
|  | DVT in medical history      | 71          | 1           | 0.77    |
|  | Coagulation disorders       | 19          | 0           | 0.99    |
|  | Bleeding disorders          | 6           | 0           | 0.80    |
|  | Smoking at time of KTx      | 385         | 2           | 0.40    |
| <b>Diabetic nephropathy</b>              |                             | 269         | 4           | 0.47    |
| <b>N arteries</b>                        | >1                          | 354         | 8           | 0.04    |
| <b>N veins</b>                           | >1                          | 54          | 1           | 0.45    |
| <b>Blood loss (mL)</b>                   | ≥500                        | 320         | 6           | 0.15    |
| <b>Intraoperative diuresis</b>           | No                          | 389         | 10          | 0.004   |
| <b>Donor type</b>                        | Living donor                | 1193        | 10          | 0.24    |
|  | DBD                         | 381         | 6           | 0.70    |
|  | DCD                         | 403         | 5           |         |
| <b>Donor age (years)</b>                 | ≥60                         | 693         | 11          | 0.10    |
| <b>Donor gender</b>                      | Male (%)                    | 962         | 10          | 0.92    |
| <b>Right kidney</b>                      |                             | 695         | 9           | 0.25    |
| <b>Ischemic times in min.</b>            | 1 <sup>st</sup> WIT         | 5.7 ± 8.5   | 5.6 ± 5.7   | 0.71    |
|  | CIT >24h                    | 14          | 1           | 0.03    |
|  | 2 <sup>nd</sup> WIT         | 30.8 ± 13.6 | 36.3 ± 19.6 | 0.14    |
| <b>Preoperative Hb</b>                   |                             | 7.4 ± 1.0   | 7.2 ± 1.1   | 0.23    |
| <b>Preoperative platelets</b>            |                             | 228 ± 85    | 213 ± 42    | 0.42    |
| <b>Antithrombotic therapy</b>            | None                        | 1344        | 15          | 0.73    |
|  | Continued VKA*              | 26          | 1           | 0.25    |
|  | APT**                       | 388         | 3           | 0.54    |
|  | Intraoperative UFH          | 193         | 1           | 0.71    |
|  | APT + intraoperative UFH    | 28          | 1           | 0.27    |
| <b>Postoperative heparin infusion</b>    |                             | 632         | 5           | 0.43    |
| <b>ABO – blood group</b>                 | Incompatible                | 72          | 2           | 0.19    |
| <b>DGF</b>                               |                             | 453         | 2           | 0.44    |

Shown are baseline characteristics in n (%). Ordinal data are given as median with IQR. Continuous data as mean ± S.D. N, number in group; CAPD, continuous ambulatory peritoneal dialysis; ASA, American society for anesthesiologists; BMI, body mass index; eGFR, estimated glomerular filtration rate; CCI, Charlson Comorbidity Index; SLE, systemic lupus erythematosus; DVT, deep venous thrombosis; DBD, donation after brain death; DCD, donation after circulatory death; WIT, warm ischemic time; CIT, cold ischemic time; VKA, Vitamin K antagonists; APT, antiplatelet therapy; UFH: unfractionated heparin. \*Administration of VKA on day of transplantation was continued and INR not corrected. †Administration of APT was continued at the day of transplantation. Second WIT was defined as the time from cold storage to recirculation (anastomosis time). CCI, which predicts the 1y mortality for a patient, was scored for all recipients [35].

**Table 2.** Incidence of postoperative bleeding and baseline characteristics.

| Baseline characteristics of KTx patients |                             | Cases       |                  |         |
|--|-----------------------------|-------------|------------------|---------|
| Characteristics                          |                             | No bleeding | Bleeding ≤7 days | P-value |
| <b>n</b>                                 |                             | 1912        | 88               |         |
| <b>gender (%)</b>                        | Male                        | 1157        | 51               | 0.63    |
| <b>Age in years</b>                      | ≥50                         | 1255        | 61               | 0.48    |
| <b>Preemptive KTx</b>                    | Hemodialysis                | 581         | 37               | 0.02    |
| <b>Dialysis-dependent KTx</b>            | CAPD                        | 1006        | 40               |         |
|  |                             | 324         | 11               | 0.64    |
| <b>Months of dialysis</b>                |                             | 22 ± 27     | 19 ± 24          | 0.32    |
| <b>Ethnicity</b>                         | Non-Caucasian               | 246         | 19               | 0.02    |
| <b>ASA score</b>                         |                             | 3 (3 – 3)   | 3 (3 – 3)        | 0.06    |
| <b>BMI in kg/m<sup>2</sup></b>           | ≥30                         | 410         | 11               | 0.04    |
| <b>Baseline eGFR</b>                     | ≥10                         | 574         | 36               | 0.03    |
| <b>CCI score</b>                         |                             | 4 (3 – 6)   | 5 (3 – 6)        | 0.02    |
| <b>Co-morbidities</b>                    | Diabetes                    | 384         | 21               | 0.39    |
|  | SLE                         | 27          | 0                | 0.26    |
|  | Cardiovascular disease      | 433         | 36               | <0.001  |
|  | Peripheral vascular disease | 152         | 11               | 0.13    |
|  | Hypertension                | 1129        | 53               | 0.82    |
|  | DVT in medical history      | 68          | 4                | 0.56    |
|  | Coagulation disorders       | 19          | 0                | 0.35    |
|  | Bleeding disorders          | 6           | 0                | 1.00    |
|  | Smoking at time of KTx      | 378         | 9                | 0.02    |
| <b>Diabetes nephropathy</b>              |                             | 256         | 17               | 0.11    |
| <b>N arteries</b>                        | >1                          | 342         | 20               | 0.24    |
| <b>N veins</b>                           | >1                          | 55          | 0                | 0.11    |
| <b>Blood loss (mL)</b>                   | ≥500                        | 304         | 22               | 0.12    |
| <b>Intraoperative diuresis</b>           | no                          | 376         | 23               | 0.13    |
| <b>Donor type</b>                        | Living donor                | 1151        | 52               | 0.84    |
|  | DBD                         | 373         | 14               | 0.23    |
|  | DCD                         | 386         | 22               |         |
| <b>Donor age (years)</b>                 | ≥60                         | 664         | 40               | 0.04    |
| <b>Donor gender</b>                      | Male (%)                    | 930         | 42               | 0.85    |
| <b>Right kidney</b>                      |                             | 677         | 27               | 0.54    |
| <b>Ischemic times in min</b>             | 1 <sup>st</sup> WIT         | 5.4 ± 7.0   | 5.7 ± 6.1        | 0.70    |
|  | CIT > 24h                   | 14          | 1                | 0.42    |
|  | 2 <sup>nd</sup> WIT         | 31.1 ± 13.8 | 26.1 ± 11.0      | 0.001   |
| <b>Preoperative Hb</b>                   |                             | 7.4 ± 1.0   | 7.3 ± 1.0        | 0.46    |
| <b>Preoperative platelets</b>            |                             | 228 ± 85    | 226 ± 75         | 0.94    |
| <b>Antithrombotic therapy</b>            | None                        | 1304        | 55               | 0.26    |
|  | Continued VKA*              | 21          | 6                | 0.001   |
|  | APT**                       | 371         | 20               | 0.44    |
|  | Intraoperative UFH          | 189         | 5                | 0.15    |
|  | APT + intraoperative UFH    | 27          | 2                | 0.37    |
| <b>Postoperative heparin infusion</b>    |                             | 593         | 44               | <0.001  |
| <b>ABO – blood group</b>                 | incompatible                | 72          | 2                | 0.77    |
| <b>DGF</b>                               |                             | 432         | 23               | 0.41    |


Shown are baseline characteristics in n (%). Ordinal variables are shown as median with interquartile range. Continuous variables are shown as mean ± S.D. N, number in group; CAPD, continuous ambulatory peritoneal dialysis; ASA, American society for anesthesiologists; BMI, body mass index; eGFR, estimated glomerular filtration rate; CCI, Charlson Comorbidity Index; SLE, systemic lupus erythematosus; DVT, deep venous thrombosis; DBD, donation after brain death; DCD, donation after circulatory death; WIT, warm ischemic time; CIT, cold ischemic time; VKA, Vitamin K antagonists; AP, antiplatelet therapy; UFH, unfractionated heparin. \* Administration of VKA on day of transplantation, medication was continued and INR not corrected. † Administration of APT was continued at the day of transplantation. Second WIT was defined as the time from cold storage to recirculation (anastomosis time).

### Risk factors for TEC

Univariable analysis (Table 3) shows that KTx with multiple donor arteries increases the risk for the development of TEC by 2.8-fold [odds ratio (OR) 2.79 (95% CI: 1.15–6.79),  $P=0.04$ ]. For every recipient with a BMI  $>30$  kg/m<sup>2</sup>, the added risk for developing TEC is almost threefold [OR 2.85 (95% CI: 1.19–6.82),  $P=0.03$ ]. Intraoperative diuresis was associated with decreased risk of TEC [OR 0.27 (95% CI: 0.11–0.65),  $P=0.004$ ]. A multivariable regression analysis could not be performed without the risk of underfitting the model owing to small numbers.

### Incidences of postoperative bleeding

Postoperative bleeding occurred in 88 (4.4%) cases  $\leq 7$  days after transplantation. Forty-six (52%) cases occurred in the control group, 15 (17%) in the VKA group, 20 (23%) in the APT group, five (6%) in the UFH group and two (2%) in the APT + UFH group (Fig. 3). Incidence of bleeding varied significantly between the treatment groups ( $P=0.006$ ). Of all patients with postoperative bleeding, 47 required surgical intervention with or without blood transfusion, and 17 required only a blood transfusion. Median time for development of bleeding was on the second postoperative day (1–4) ( $n=45$ , 51%), with a peak on the first day ( $n=36$ , 41%) (Fig. 2).



**Figure 3.** Incidence (%) of bleeding per treatment group. APT, antiplatelet therapy; VKA, Vitamin K antagonists; UFH, unfractionated heparin (given intraoperatively).

**Table 3.** Univariable analysis for possible risk factors for TEC

| <b>Risk factors for Thromboembolic complications</b><br>(Univariable analysis using Enter method of binary logistics) | <b>Odds ratio (95% CI)</b> | <b>P value</b> |
|---|----------------------------|----------------|
| <b>ABO-incompatible</b>   | 2.69 (0.61 – 11.81)        | 0.19           |
| <b>Preoperative VKA-therapy (not stopped, INR not corrected)</b>  | 3.76 (0.49 – 29.04)        | 0.25           |
| <b>Preoperative antiplatelet therapy</b>  | 0.68 (0.20 – 2.33)         | 0.78           |
| <b>Anticoagulation: Intraoperatively</b>  | 0.46 (0.06 – 3.47)         | 0.71           |
| <b>Postoperative heparin infusion</b>   | 0.67 (0.24 – 1.83)         | 0.43           |
| <b>Arteries &gt;1</b>   | 2.79 (1.15 – 6.79)         | 0.04           |
| <b>Blood loss &gt;500 mL</b>  | 2.05 (0.75 – 5.58)         | 0.23           |
| <b>CAPD (yes)</b>   | 1.55 (0.56 – 4.25)         | 0.38           |
| <b>Coagulation disorder (yes)</b>   | 0.99 (0.99 – 0.99)         | 1.00           |
| <b>Cold ischemic time per 1 hour increase</b>   | 1.08 (0.98 – 1.20)         | 0.14           |
| <b>DGF (yes)</b>  | 0.56 (0.16 – 1.91)         | 0.44           |
| <b>Diabetic nephropathy (yes)</b>   | 1.50 (0.50 – 4.48)         | 0.52           |
| <b>Donation of the right kidney</b>   | 1.71 (0.68 – 4.33)         | 0.25           |
| <b>Donor age (&lt;60 versus &gt;60)</b>   | 2.04 (0.86 – 4.82)         | 0.10           |
| <b>Donor gender (female)</b>  | 1.69 (0.71 – 3.99)         | 0.23           |
| <b>Donor (deceased)</b>   | 1.67 (0.71 – 3.95)         | 0.24           |
| <b>Deceased donor type (DBD)</b>  | 1.27 (0.38 – 4.19)         | 0.70           |
| <b>DVT medical history (yes)</b>  | 1.34 (0.18 – 10.15)        | 0.54           |
| <b>Ethnicity (non-white)</b>  | 0.34 (0.05 – 2.55)         | 0.50           |
| <b>Intraoperative diuresis (yes)</b>  | 0.27 (0.11 – 0.65)         | 0.004          |
| <b>Preemptive transplantation (yes)</b>   | 1.12 (0.45 – 2.79)         | 0.81           |
| <b>Recipient age (≥50)</b>  | 0.69 (0.29 – 1.65)         | 0.40           |
| <b>Recipient BMI (≥30)</b>  | 2.85 (1.19 – 6.82)         | 0.03           |
| <b>Recipient gender (female)</b>  | 1.69 (0.71 – 3.99)         | 0.23           |
| <b>SLE (yes)</b>  | 3.76 (0.49 – 29.04)        | 0.25           |
| <b>Smoking (yes)</b>  | 0.45 (0.10 – 1.94)         | 0.40           |
| <b>Time on dialysis (per 1 year increase)</b>   | 0.89 (0.63 – 1.26)         | 0.51           |
| <b>Second warm ischemic time (≥45 min)</b>  | 1.79 (0.65 – 4.97)         | 0.23           |
| <b>Recipient BMI per 5 kg/m<sup>2</sup> increase</b>  | 0.96 (0.50 – 1.84)         | 0.90           |
| <b>Charlson comorbidity index score per 1 point increase</b>  | 0.86 (0.61 – 1.20)         | 0.37           |
| <b>ASA score per 1 point increase</b>   | 1.17 (0.32 – 4.23)         | 0.81           |

Odds ratio is presented with 95% confidence interval (CI). An OR above 1.00 implies an increased risk compared to its equivalent. An OR below 1.00 corresponds to a decreased risk. *P*-value <0.05 was considered statistically significant. VKA, Vitamin K antagonists; INR, international normalized ratio; CAPD, continuous ambulatory peritoneal dialysis; DGF, delayed graft function; DBD, donation after brain death; DVT, deep venous thrombosis; BMI, body mass index; SLE, systemic lupus erythematosus; ASA, American society of anesthesiologists.

**Risk factors for bleeding  $\leq 7$  days after transplantation**

In univariable analysis (Table 4), continued use of VKA [OR 10.13 (95% CI: 5.33–19.52),  $P < 0.001$ ] and postoperative continuous heparin infusion increased the risk [OR 2.22 (95% CI: 1.45–3.42),  $P < 0.001$ ] for postoperative bleeding. Donor age  $> 60$  years [OR 1.60 (95% CI: 1.04–2.46),  $P = 0.04$ ] was associated with a 1.6-fold increased risk. Being of non-Caucasian ethnicity increased the risk nearly twofold [OR 1.91 (95% CI: 1.13–3.24),  $P = 0.01$ ] and patients suffering from CVD had a 2.4-fold increased risk [OR 2.41 (95% CI: 1.55–3.75),  $P < 0.001$ ]. Furthermore, being pre-emptively transplanted increased the risk by 1.7-fold [OR 1.70 (95% CI: 1.10–2.62),  $P = 0.02$ ] and every point increase on the American Society for Anesthesiologists (ASA)-scale by 2.1-fold [OR 2.10 (95% CI: 1.04–4.23),  $P = 0.04$ ]. A second warm ischemic time, defined as time from cold storage to recirculation (anastomosis time),  $> 45$  minutes [OR 0.46 (95% CI: 0.21–1.00),  $P = 0.04$ ] and smoking [OR 0.46 (95% CI: 0.23–0.93),  $P = 0.03$ ] reduced the risk of developing postoperative bleeding by more than half. Every increase of  $5 \text{ kg/m}^2$  in recipient BMI decreased the risk by more than a quarter [OR 0.72 (95% CI: 0.52–0.99)  $P = 0.05$ ].

**Multivariable regression analysis for postoperative bleeding  $\leq 7$  days**

For multivariable adjusted analyses, the following variables were entered in the model: UFH VKA, APT, postoperative heparin, non-Caucasian ethnicity of the recipient, pre-emptive KTx, presence of CVD, BMI per  $1 \text{ kg/m}^2$  increase, donor age  $\geq 60$ , intraoperative blood loss  $\geq 500 \text{ mL}$ , CIT per hour increase, smoking, presence of peripheral vascular disease (PVD) and diabetic nephropathy (Table 5). Hosmer-Lemeshow test showed fitness of the model ( $P = 0.98$ ). The C-statistic of this model is 0.75, indicating a high degree of discrimination. Pre-existing CVD [OR 2.01 (95% CI: 1.18–3.42),  $P = 0.010$ ], preemptive KTx [OR 2.23 (95% CI: 1.28–3.89),  $P = 0.005$ ], continued use of VKA [OR 6.60 (95% CI: 2.95–14.77),  $P < 0.001$ ] and postoperative heparin infusion [OR 1.69 (95% CI: 1.00–2.85),  $P = 0.049$ ] remained independently associated with risk for postoperative bleeding  $\leq 7$  days after KTx. After adjustment for VKA therapy, which is indicated in certain cardiovascular conditions and could thus be a confounding factor, CVD remained a significant risk factor for bleeding [OR 2.46, (95% CI: 1.47–4.12),  $P = 0.001$ ]. When patients with postoperative heparin infusion ( $n = 637$ ) were removed from the equation, pre-emptive KTx remained associated with bleeding [OR 3.24 (95% CI: 1.42–7.41),  $P < 0.01$ ]. Stratification for transplant center did not show significant difference in bleeding in the pre-emptively transplanted patients ( $P = 0.23$ ).

**Table 4.** Univariable analysis for possible risk factors for postoperative bleeding.

| <b>Risk factors for bleeding</b><br>(Univariable analysis using Enter method of binary logistics) | <b>Odds ratio (95% CI)</b> | <b>P value</b> |
|---|----------------------------|----------------|
| <b>ABO-incompatible</b>   | 0.59 (0.14 – 2.45)         | 0.77           |
| <b>Preoperative VKA-therapy (not stopped, INR not corrected)</b>                                  | 10.13 (5.33 – 19.25)       | <0.001         |
| <b>Preoperative antiplatelet therapy</b>  | 1.23 (0.74 – 2.04)         | 0.44           |
| <b>Intraoperative heparin</b>   | 0.55 (0.22 – 1.36)         | 0.15           |
| <b>Postoperative heparin infusion</b>   | 2.22 (1.45 – 3.42)         | <0.001         |
| <b>Arteries &gt;1</b>   | 1.35 (0.81 – 2.26)         | 0.24           |
| <b>Blood loss ≥500 mL</b>   | 1.50 (0.90 – 2.49)         | 0.12           |
| <b>CAPD (yes)</b>   | 0.70 (0.37 – 1.34)         | 0.28           |
| <b>Cold ischemic time per 1 hour increase</b>   | 1.06 (1.00 – 1.12)         | 0.05           |
| <b>DGF (yes)</b>  | 1.23 (0.75 – 2.00)         | 0.41           |
| <b>Diabetic nephropathy (yes)</b>   | 1.55 (0.90 – 2.67)         | 0.11           |
| <b>Donation of the right kidney</b>   | 0.86 (0.53 – 1.38)         | 0.54           |
| <b>Donor age (≥60)</b>  | 1.56 (1.02 – 2.40)         | 0.04           |
| <b>Donor gender (female)</b>  | 1.11 (0.72 – 1.71)         | 0.63           |
| <b>Donor (deceased)</b>   | 1.05 (0.68 – 1.62)         | 0.84           |
| <b>Deceased donor type (DBD)</b>  | 0.66 (0.33 – 1.31)         | 0.23           |
| <b>Duration dialysis (per 1 year increase)</b>  | 0.93 (0.80 – 1.08)         | 0.36           |
| <b>Ethnicity (non-white)</b>  | 1.88 (1.11 – 3.18)         | 0.02           |
| <b>Intraoperative diuresis (yes)</b>  | 0.68 (0.41 – 1.12)         | 0.13           |
| <b>Preemptive (yes)</b>   | 1.66 (1.08 – 2.57)         | 0.02           |
| <b>Recipient gender (female)</b>  | 1.11 (0.72 – 1.71)         | 0.63           |
| <b>Recipient age (&gt;50)</b>   | 1.18 (0.75 – 1.88)         | 0.48           |
| <b>Second warm ischemic time (≥ 45 minutes)</b>   | 0.45 (0.21 – 0.98)         | 0.04           |
| <b>Smoking (yes)</b>  | 0.46 (0.23 – 0.92)         | 0.02           |
| <b>Recipient BMI per 5 kg/m<sup>2</sup> increase</b>  | 0.73 (0.53 – 1.01)         | 0.05           |
| <b>Charlson comorbidity index score per 1 point increase</b>                                      | 1.06 (0.93 – 1.21)         | 0.36           |
| <b>ASA score per 1 point increase</b>   | 2.14 (1.06 – 4.31)         | 0.03           |
| <b>Cardiovascular disease</b>   | 2.37 (1.53 – 3.67)         | <0.001         |
| <b>Peripheral vascular disease</b>  | 1.65 (0.86 – 3.18)         | 0.13           |
| <b>Recipient BMI &gt;30 kg/m<sup>2</sup></b>  | 0.52 (0.28 – 0.99)         | 0.04           |

Odds ratio with 95% confidence interval (CI). An OR above 1.00 implies an increased risk compared to its equivalent. An OR below 1.00 corresponds to a decreased risk.  $P < 0.05$  was considered statistically significant. VKA, Vitamin K antagonists; INR, international normalized ratio; CAPD, continuous ambulatory peritoneal dialysis; DGF, delayed graft function; DBD, donation after brain death; BMI, body mass index; ASA, American society of anesthesiologists.

**Table 5.** Multivariable regression analysis for risk factors for postoperative bleeding within 7 days after kidney transplantation

| <b>Risk factors for bleeding</b><br>(Multivariable analysis using Enter method of binary logistics) | <b>Odds ratio (95% CI)</b> | <b>P value</b> |
|---|----------------------------|----------------|
| <b>Intraoperative heparin</b>   | 1.22 (0.43 – 3.45)         | 0.711          |
| <b>Vitamin K antagonists</b>  | 6.60 (2.95 – 14.77)        | <0.001         |
| <b>Postoperative heparin infusion</b>   | 1.69 (1.00 – 2.85)         | 0.049          |
| <b>Antiplatelet therapy</b>   | 1.51 (0.80 – 2.85)         | 0.204          |
| <b>Ethnicity of the recipient (non-Caucasian)</b>   | 1.85 (0.98 – 3.49)         | 0.058          |
| <b>Preemptive transplantation</b>   | 2.23 (1.28 – 3.89)         | 0.005          |
| <b>BMI per 1 kg/m<sup>2</sup> increase</b>  | 0.93 (0.87 – 0.98)         | 0.011          |
| <b>Donor age ≥60</b>  | 1.63 (0.99 – 2.69)         | 0.054          |
| <b>Intraoperative blood loss ≥500mL</b>   | 1.60 (0.91 – 2.83)         | 0.103          |
| <b>Cold ischemic time per 1 hour increase</b>   | 1.02 (0.97 – 1.06)         | 0.450          |
| <b>Smoking at time of transplantation</b>   | 0.39 (0.17 – 0.89)         | 0.025          |
| <b>Cardiovascular disease</b>   | 2.01 (1.18 – 3.42)         | 0.010          |
| <b>Peripheral vascular disease</b>  | 1.36 (0.62 – 3.01)         | 0.446          |
| <b>Diabetic nephropathy</b>   | 0.86 (0.42 – 1.76)         | 0.680          |

Odds ratio with 95% confidence interval. All factors adjusted for risk factors in the table.  $P < 0.05$  was considered statistically significant. CI, confidence interval; BMI, body mass index.

## DISCUSSION

To our knowledge, we report on the largest series focusing on postoperative thrombo-embolic and bleeding complications after KTx. We identified a 1.1% incidence of early TEC and 4.4% bleeding complications. This is lower than reported in the literature.<sup>8–11,22,23</sup> High BMI and multiple donor arteries were associated with increased risk for TEC. Pre-emptive KTx, use of VKA, CVD, and postoperative heparin infusion were independent risk factors for early (re-) bleeding. Interestingly intraoperative heparin, APT, or the combination were not associated with an increased risk. TEC or bleeding occurred mostly within the first days after KTx, with the majority on the first postoperative day, which has been reported before.<sup>22</sup> TEC in the first post-transplant week, were predominantly RGT, whereas DVT and PE were rare or absent. Because KTx recipients are reported to have a sevenfold higher risk of venous thromboembolism compared to the general population, which confers an increased risk of graft loss and even death,<sup>9,24</sup> our results can help in identifying the patients most at risk and provide a starting-point for prospective studies in order to develop preventive strategies. Since therapeutic options for RGT are scarce, antithrombotic prophylaxis may decrease this risk.

While some data considering antithrombotic prophylaxis in KTx exist, these reports are limited by their sample size. Therefore, a clear answer as to whether antithrombotic therapy increases bleeding risk had yet to be found. Pawlicki *et al.*<sup>23</sup> reported an association between

increased risk for bleeding and antithrombotic prophylaxis, but this study was limited by sample size ( $n = 67$ ), and suboptimal methodology: hematomas of  $\geq 4\text{cm}$ , with or without graft compression were scored as bleeding events. In general, hematomas of  $\geq 4\text{cm}$  are common after KTx and rarely have any clinical relevance. Our inclusion criteria for bleeding were stricter, and therefore the incidence of postoperative bleeding was relatively low compared to other studies (4.9–25.4%).<sup>22,23</sup> The incidence is reported to decline to 0.2–1.9%, if only a re-operation is considered clinically relevant.<sup>25</sup> Considered all above, our incidence seems to be an accurate representation of clinically relevant bleeding after KTx. High BMI was found to be associated with increased risk for TEC, while it reduced the risk for bleeding. It is known that obesity leads to hypercoagulability and several explanations for this finding have been considered. Patients with higher BMI could have more space for bleeding and would therefore be less likely to develop bleeding with compression on the graft or high body weight could possibly tamponade the bleeding.<sup>22,26</sup> Difficulty in performing duplex ultrasound on obese patients could lead to underreporting of bleeding, although our inclusion criteria for bleeding should have been able to identify these patients as well. The higher volume of surrounding tissue could also lead to impaired blood flow and thus increase the risk for thrombosis by twofold. Contradictory results have been reported regarding the increased risk for TEC (especially renal artery thrombosis) in case of multiple donor arteries<sup>7,27,28</sup> and this finding might therefore be of less significance in a multivariable model. Another study on bleeding risks after perioperative anticoagulation concluded that the utilization of antithrombotic prophylaxis does neither increase the incidence nor the risk for bleeding in the perioperative period, except for postoperative heparin infusion.<sup>29</sup> Heparin infusion, starting within 24h after surgery, has been associated with an increased risk for bleeding before,<sup>30</sup> as in our analysis, whereas the prophylactic use of heparin (5000 IU s.c. twice daily) is reported to be safe.<sup>31</sup> Others reported an increased risk of bleeding after continued VKA therapy as well, but concluded that the indication for VKA therapy was nonmodifiable in certain patients.<sup>32</sup> We can concur this finding since all patients on continued VKA therapy in our analysis had a vital indication for anticoagulation therapy, i.e., due to paroxysmal atrial fibrillation with high CHA2DS2-VASc scores. In all cases, the treating physicians were aware of the possible complications and deemed discontinuing preoperatively as more threatening than the risk of a postoperative bleeding. Aside from VKA-therapy, often indicated in certain cardiovascular diseases, CVD was associated with an increased risk for bleeding, even after correction for VKA or APT, most likely explained by the technical challenges of transplanting patients with a high burden of CVD. A previous study mentioned that pre-emptive KTx is protective against thrombosis.<sup>33</sup> Interestingly, we saw an increased risk for bleeding in our pre-emptively transplanted cohort. After adjusting for intraoperative heparin, predominantly given to pre-emptive patients in one center, pre-emptive transplantation remained an independent risk factor. To our knowledge, the general argument to refrain from anticoagulation during KTx is often the belief that patients on dialysis, in contrast to pre-emptive patients, are considered hypocoagulable, because of



the residual effect of heparin used during dialysis and the continuous activation of platelets through contact with the dialysis membrane. However, uremic toxins, which influence platelet function, develop in all patients with renal failure and recent insights have shown that dialysis could even lead to reduced risk of bleeding due to removal of these uremic toxins.<sup>16,17</sup> Surgical aspects, such as cross-clamping and anastomoses of vessels, may also overcome the theoretically guarding effects of uremia against thrombosis.<sup>8</sup> Therefore, dialysis-dependent patients are at risk of both bleeding and thrombotic complications. Recent analysis has shown that pre-emptively transplanted patients and dialysis patients have a comparable ability for platelet and coagulation activation prior to transplantation.<sup>18</sup> Therefore, differences might be found in platelet function, which could be worse in pre-emptive patients compared to dialysis-dependent patients than previously thought, since they do not benefit from the potentially beneficial effect of hemodialysis on platelet dysfunction.

A few limitations of this study need to be addressed. First, due to low event numbers multivariable analysis for TEC was not feasible without leading to under fitting the model and thus a detailed analysis of potential risk factors is missing. Considering our incidence, a similar multivariable analysis as performed for bleeding, would require nearly 8000 KTx recipients. Second, because of the retrospective study design and relatively low incidence, potential confounding risk factors may have been missed. A randomized study or propensity-matched cohort would probably have given a more robust outcome. However, given the many confounders and low incidences, this requires many patients, making a prospective study very challenging. Despite the skewed distribution in our study, we present the largest series with data from a real-world experience and provide reliable insights in risk factors for both TEC and bleeding after KTx. Third, postoperative antithrombotic therapy was not included in this study except for 5-day heparin infusion. When preoperative anticoagulants were stopped, reinitiation usually did not take place within 1–2 days after KTx, unless vital indications for anticoagulation stated otherwise. Since most TEC or bleeding occurred within the first postoperative day, we expect that this would not have significantly affected our results. Furthermore, DVT and PE might have required a longer follow-up until 30 days post-transplant, considered a reported cumulative risk.<sup>34</sup> In this study, we aimed at analyzing early postoperative complications in relation to perioperative antithrombotic prophylaxis.

Our results show that continued APT and intraoperative heparin do not increase the incidence of bleeding after KTx and that it is safe to use these agents in order to prevent early postoperative TEC. We advise that VKA should only be continued in patients with a vital indication for anticoagulation. Despite the significantly increased risk, patients using VKA should not be refrained from KTx, but instead should be monitored closely for early signs of postoperative bleeding, with i.e., daily duplex imaging in the first five postoperative days and prophylactic placing of surgical drains seems advised. Postoperative heparin infusion should be refrained from, as several studies have now reported increased bleeding risk with unclear advantages for prevention of TEC. There is still a lot of uncertainty about the use of

antithrombotic prophylaxis during KTx. A cutoff point based solely on dialysis dependence seems very arbitrary and unfounded because pre-emptive patients also have a poor kidney function, with the associated risks of an impaired coagulation. Perhaps new criteria should be established in which a high-risk group is defined who would benefit most from antithrombotic prophylaxis perioperatively. Given the dogmas that prevail, we hope this study will add new insights and data into this longstanding and recurrent problem. Further research is needed to investigate the adjusted risk factors for early TEC and the possible additional advantages of intraoperative heparinization during KTx.

## **ACKNOWLEDGEMENTS**

The authors would like to thank AA Rijkse, MD, for her assistance with the statistics used in this study.

## REFERENCES

- Penny MJ, Nankivell BJ, Disney AP, Byth K, Chapman JR. Renal graft thrombosis. A survey of 134 consecutive cases. *Transplantation* 1994; 58: 565.
- Bakir N, Sluiter WJ, Ploeg RJ, van Son WJ, Tegzess AM. Primary renal graft thrombosis. *Nephrol Dial Transplant* 1996; 11: 140.
- Orlic P, Vukas D, Drescik I, et al. Vascular complications after 725 kidney transplantations during 3 decades. *Transplant Proc* 2003; 35: 1381.
- Garcia CD, Bittencourt VB, Pires F, et al. Renal Transplantation in Children Younger Than 6 Years Old. *Transplant Proc* 2007; 39: 373.
- Ojo AO, Hanson JA, Wolfe RA, et al. Dialysis modality and the risk of allograft thrombosis in adult renal transplant recipients. *Kidney Int*. 1999; 55: 1952
- Hamed MO, Chen Y, Pasea L, et al. Early Graft Loss After Kidney Transplantation: Risk Factors and Consequences. *Am J Transplant* 2015; 15: 1632.
- Keller AK, Jorgensen TM, Jespersen B. Identification of Risk Factors for Vascular Thrombosis May Reduce Early Renal Graft Loss: A Review of Recent Literature. *J Transplant* 2012; 2012: 1.
- Humar A, Johnson EM, Gillingham KJ, et al. Venous thromboembolic complications after kidney and kidney-pancreas transplantation: a multivariate analysis. *Transplantation* 1998; 65: 229.
- D. Poli, M. Zanazzi EA. Renal transplant recipients are at high risk for both symptomatic and asymptomatic deep vein thrombosis. *J Thromb Haemost* 2006; 4: 988.
- Vanrenterghem Y, Lerut T, Roels L, et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. *Lancet* 1985; 325 : 999.
- Allen RD, Michie CA, Murie JA, Morris PJ. Deep venous thrombosis after renal transplantation. *Surg Gynecol Obstet* 1987; 164: 137.
- Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. *Chest* 2001; 199: 132S.
- Bani-Hani MG, Al-Khaffaf H, Titi M a, Jaradat I. Interventions for preventing venous thromboembolism following abdominal aortic surgery. *Cochrane Database Syst Rev* 2008; (1): CD005509.
- Quigley FG, Jamieson GG, Lloyd JV, Faris IB. Monitoring of heparin in vascular surgery. *J Vasc Surg* 1988; 8: 125.
- Lutz J, Menke J, Sollinger D, Schinzel H, Thürmel K. Haemostasis in chronic kidney disease. *Nephrol Dial Transplant* 2014; 29: 29.
- Zachée P, Vermeylen J, Boogaerts MA. Hematologic aspects of end-stage renal failure. *Ann Hematol* 1994; 69: 33.
- Nieuwenhuijs-Moeke GJ, van den Berg TAJ, Bakker SJL, et al. Preemptively and non-preemptively transplanted patients show a comparable hypercoagulable state prior to kidney transplantation compared to living kidney donors. *PLoS One* 2018; 13:e0200537
- Tikkinen KAO, Craigie S, Agarwal A, et al. Procedure-specific Risks of Thrombosis and Bleeding in Urological Non-cancer Surgery: Systematic Review and Meta-analysis. *Eur Urol* 2018; 73: 236.
- Zorgdrager M, Lange JFM, Krikke C, et al. Chronic Inguinal Pain After Kidney Transplantation, a Common and Underexposed Problem. *World J Surg* 2017; 41: 630.
- Ooms LSS, Roodnat JI, Dor FJMF, et al. Kidney retransplantation in the ipsilateral iliac fossa: A surgical challenge. *Am J Transplant* 2015; 15: 2947.
- Hachem LD, Ghanekar A, Selzner M, Famure O, Li Y, Kim SJ. Postoperative surgical-site hemorrhage after kidney transplantation: incidence, risk factors, and outcomes. *Transpl Int* 2017; 30: 474.
- Pawlicki J, Cierpka L, Król R, Ziaja J. Risk Factors for Early Hemorrhagic and Thrombotic Complications After Kidney Transplantation. *Transplant Proc* 2011; 43: 3013.

23. Lam NN, Garg AX, Knoll GA, *et al.* Venous Thromboembolism and the Risk of Death and Graft Loss in Kidney Transplant Recipients. *Am J Nephrol* 2017; 46: 343.
24. Dimitroulis D, Bokos J, Zavos G, *et al.* Vascular Complications in Renal Transplantation: A Single-Center Experience in 1367 Renal Transplantations and Review of the Literature. *Transplant Proc* 2009; 41: 1609.
25. Kornblith LZ, Howard B, Kunitake R, *et al.* Obesity and clotting: Body mass index independently contributes to hypercoagulability after injury. *J Trauma Acute Care Surg* 2015; 78: 30.
26. Zorgdrager M, Krikke C, Hofker SH, Leuvenink HGD, Pol RA. Multiple Renal Arteries in Kidney Transplantation: A Systematic Review and Meta-Analysis. *Ann Transplan* 2016; 21: 469. <https://doi.org/10.12659/AOT.898748>
27. Lafranca JA, Bruggen M Van, Kimenai HJAN, *et al.* Vascular multiplicity should not be a contra-Indication for live kidney donation and transplantation. *PLoS One* 2016; 11: e0153460. <https://doi.org/10.1371/journal.pone.0153460>
28. Eng M, Brock G, Li X, *et al.* Perioperative anticoagulation and antiplatelet therapy in renal transplant: is there an increase in bleeding complication? *Clin Transplant* 2011; 25: 292.
29. Mathis AS, Davé N, Shah NK, Friedman GS. Bleeding and Thrombosis in High-Risk Renal Transplantation Candidates Using Heparin. *Ann Pharmacother* 2004; 38: 537.
30. Ng JCY, Leung M, Landsberg D. Evaluation of heparin anticoagulation protocols in post-renal transplant recipients (EHAP-PoRT study). *Can J Hosp Pharm* 2016; 69: 114.
31. Musetti C, Quaglia M, Cena T, *et al.* Impact of pre-transplant antiaggregant and anticoagulant therapies on early hemorrhagic and cardiovascular events after kidney transplantation. *J Nephrol* 2015; 28: 757.
32. Luna E, Cerezo I, Collado G, *et al.* Vascular thrombosis after kidney transplantation: Pre-disposing factors and risk index. *Transplant Proc* 2010; 42: 2928.
34. Tikkinen KAO, Agarwal A, Craigie S, *et al.* Systematic reviews of observational studies of risk of thrombosis and bleeding in urological surgery (ROTBUS): Introduction and methodology. *Syst Rev* 2014; 3: 150.
35. Grosso G, Corona D, Mistretta A, *et al.* Predictive value of the charlson comorbidity index in kidney transplantation. *Transplant Proc* 2012; 44: 1859.

